Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: David Jones who wrote (2466)	5/23/1999 7:23:00 AM
From: BB BOB	Read Replies (1) \| Respond to of 4140

Well David maybe ,maybe not...I'm looking for a slight dip over next couple of weeks then a nice run for a week or so into the July panel.After a preliminary approval,which could be announced at that time,then a final approval perhaps in October.This is when it can really get interesting,as FUND MANAGERS will take a long hard look at this one for long term hold,(this is millions of shares boys and girls!!)reason being is the royalty that the company retains from every procedure ,this brings in a continual revenue that will grow over earnings report after earnings report.Look for stock splits and tremendous price appreciation for years to come.I guess a major key here is how good is the management team and do will they care about the shareholders??Just my thoughts folks.. Regards, Bob

To: David Jones who wrote (2466)	5/23/1999 8:17:00 AM
From: emil	Read Replies (1) \| Respond to of 4140

>note: Sorry emil I seen your posts and I sold into the 14's I didn't see the squeeze coming, I just went with the tick< No comprendo? Squeeze? Are you referring to my 'sell/buy options, not stock idea?

To: David Jones who wrote (2466)	5/23/1999 12:38:00 PM
From: Gordon A. Langston	Read Replies (1) \| Respond to of 4140

David If i am not mistaken the cap value of SNRS is much higher than was VISX or BEAM or any other laser vision stock at the same time in the approvaL process. It shows up in Hank Greenburg column and he says he can't believe it is valued so high with no revenues and no approval. Then it shows up on overvalued stock lists for shorters to ponder. We are definitely at the crossroads and the shorts have about as much control of this as they ever will. Once they see that their risk out weighs their reward we will be cruisin. Gordon